Al-kawkab Scientific Bureau Pharmaceutical Import Profile — Jordan (DGFT 2022–2026)

Name: Al-kawkab Scientific Bureau Pharmaceutical Import Records from India — 3 Products, $7.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Al-kawkab Scientific Bureau — Pharmaceutical Importer Profile (2026) | 3 Products, $7.8M Trade | TransData Nexus

Al-kawkab Scientific Bureau

Pharmaceutical Importer · Jordan · Advanced Antibiotics Focus · $7.8M Total Trade · DGFT Verified

Al-kawkab Scientific Bureau is a pharmaceutical importer based in Jordan with a total trade value of $7.8M across 3 products in 3 therapeutic categories. Based on 156 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Al-kawkab Scientific Bureau sources from 1 verified Indian supplier, with Micro Labs Limited accounting for 100.0% of imports.

Al-kawkab Scientific Bureau — Import Portfolio & Supplier Network

Al-kawkab Scientific Bureau import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Al-kawkab Scientific Bureau?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$21.6M	596	100.0%

Al-kawkab Scientific Bureau sources from 1 verified Indian supplier across 346 distinct formulations. The sourcing is highly concentrated — Micro Labs Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Al-kawkab Scientific Bureau Import?

Formulation	Value	Ships
Pulmoxyl 500 (amoxycillin capsules BP	$411.2K	9
Pulmoxyl 500 (amoxicillin capsules BP	$203.2K	5
Bactoclav 625 (amoxycillin 500MG +	$200.0K	4
Supixime-100 dry syrup(cefixime for	$200.0K	4
Avas 20 (atorvastatin 20MG tablets) Pack(3x10`s) (qty-102048.000	$150.0K	3
Avas-40 (atorvastatin tablets 40MG )pack3x10`s,qty 102349.000 fac inv no	$150.0K	3
Pulmoxyl 500 (amoxycillin capsules BP 500MG Pack 10x10`s,qty	$150.0K	3
Cefex 500 ( (cefalexin capsules 500MG BP) ) ( 10x10s ) ( qty- 39682.000	$150.0K	3
Cefex 500, (cefalexin capsules 500 MG BP) Pack (10x10`s ),(qty-48357.000	$150.0K	3
Avas-20 (atorvastain tablets 20MG ) pack3x10`s,qty	$150.0K	3
Pulmoxyl 500 (amoxycillin capsules BP 500MG ) Pack 10x10`s,qty	$150.0K	3
Pulmoxyl 500 (amoxycillin capsules BP 500MG) Pack 10x10`s,qty	$150.0K	3
Cefex 500(cefalexin capsules BP 500MG ,Pack 10x10`s,qty	$150.0K	3
Pulmoxyl 500 (amoxicillin capsules BP 500MG)Pack 10x10`s,qty	$150.0K	3
Pulmoxyl 500 (amoxicillin capsules BP 500MG) Pack 10x10`s,qty	$150.0K	3

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cefixime	Advanced Antibiotics	$5.3M	105	2.1%	4
2	Atorvastatin	Cardiovascular	$2.4M	47	0.2%	17
3	Vildagliptin	Advanced Diabetes Medications	$200.0K	4	2.0%	6

Al-kawkab Scientific Bureau imports 3 pharmaceutical products across 3 categories into Jordan totaling $7.8M.

Al-kawkab Scientific Bureau — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Al-kawkab Scientific Bureau is a pharmaceutical importer based in Jordan, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Jordanian pharmaceutical distribution network, ensuring the availability of essential medications across the country. While specific details about its headquarters and parent company are not publicly disclosed, Al-kawkab Scientific Bureau's operations are integral to the healthcare supply chain in Jordan.

2Distribution Network

Al-kawkab Scientific Bureau's distribution network encompasses various regions within Jordan, facilitating the widespread availability of imported pharmaceutical products. The company collaborates with multiple logistics partners to ensure efficient transportation and delivery of goods. However, detailed information regarding specific warehouse locations and logistics capabilities is not publicly available.

3Industry Role

In Jordan's pharmaceutical supply chain, Al-kawkab Scientific Bureau functions primarily as a wholesaler and importer. The company sources finished pharmaceutical formulations from international suppliers, notably from India, and distributes these products to various stakeholders within the healthcare sector, including hospitals, pharmacies, and clinics. This role is crucial in maintaining a steady supply of medications to meet the country's healthcare needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Al-kawkab Scientific Bureau

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Al-kawkab Scientific Bureau exhibits a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier, MICRO LABS LIMITED, which accounts for 100% of its imports. This exclusive sourcing strategy may offer benefits such as streamlined procurement processes and potential cost advantages. However, it also introduces risks associated with dependency on a single supplier, including potential supply chain disruptions and limited negotiation leverage. The stability of this relationship is critical, and any changes in the supplier's operations or market conditions could significantly impact Al-kawkab Scientific Bureau's ability to meet market demand.

2Supply Chain Resilience

The resilience of Al-kawkab Scientific Bureau's supply chain is closely tied to its exclusive relationship with MICRO LABS LIMITED. The lack of backup suppliers and limited formulation diversity may pose challenges in the event of supply disruptions. Additionally, the company's reliance on a single shipping route and potential exposure to geopolitical risks could further impact supply chain stability. Ensuring regulatory compliance and maintaining a robust relationship with MICRO LABS LIMITED are essential to mitigate these risks.

Strategic Implications

Importing Pharmaceuticals into Jordan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Jordan

1Regulatory Authority & Framework

The Jordan Food and Drug Administration (JFDA) is the primary regulatory authority overseeing the pharmaceutical sector in Jordan. The JFDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through rigorous registration and monitoring processes. Key legislation governing pharmaceutical imports includes the Pharmaceutical Establishment Licensing Regulation No. 162 of 2019, which outlines the requirements for importing, distributing, and selling pharmaceutical products in Jordan. The marketing authorization pathway for Indian generics involves obtaining approval from the JFDA, which assesses the safety, efficacy, and quality of the products before granting registration.

2Import Licensing & GMP

Import licensing in Jordan is mandatory for pharmaceutical products. Importers must obtain an import license from the Ministry of Industry, Trade, and Supply, valid for one year. Additionally, the JFDA requires that imported pharmaceutical products be manufactured in facilities that adhere to Good Manufacturing Practice (GMP) standards recognized by reputable authorities, such as the European Medicines Agency (EMA) or the World Health Organization (WHO). Importers must ensure that their suppliers possess valid GMP certificates to comply with Jordanian regulations.

Al-kawkab Scientific Bureau — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Al-kawkab Scientific Bureau's product strategy focuses on three primary therapeutic categories: Advanced Antibiotics, Cardiovascular, and Advanced Diabetes Medications. The substantial import value of Advanced Antibiotics (67.3%) and Cardiovascular medications (30.1%) indicates a strategic emphasis on addressing prevalent health concerns in Jordan. The inclusion of Advanced Diabetes Medications (2.6%) reflects a commitment to managing chronic conditions that are increasingly common in the region. This product mix aligns with the market demand for effective treatments in these therapeutic areas.

2Sourcing Profile

Al-kawkab Scientific Bureau's sourcing strategy is heavily reliant on generic drugs, primarily imported from India. The company's exclusive relationship with MICRO LABS LIMITED suggests a preference for established suppliers that can provide a diverse range of formulations. This approach allows Al-kawkab Scientific Bureau to offer a comprehensive portfolio of pharmaceutical products to the Jordanian market.

3Market Positioning

Based on its product mix, Al-kawkab Scientific Bureau serves a broad segment of the Jordanian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on essential therapeutic areas positions it as a key supplier of critical medications, catering to both acute and chronic health conditions prevalent in the country.

Seller's Guide — How to Become a Supplier to Al-kawkab Scientific Bureau

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Al-kawkab Scientific Bureau by offering alternative products or formulations that complement the existing portfolio. Identifying gaps in the current sourcing strategy, such as unmet therapeutic needs or emerging market trends, can provide avenues for collaboration. However, any new supplier must be prepared to meet the stringent regulatory requirements set by the JFDA and demonstrate the ability to deliver high-quality products consistently.

2Requirements & Qualifications

Indian exporters seeking to supply Al-kawkab Scientific Bureau must ensure that their products are registered with the JFDA and manufactured in facilities adhering to recognized GMP standards. Compliance with Jordanian labeling requirements, including Arabic language specifications, is mandatory. Additionally, exporters should be prepared to provide comprehensive documentation, including certificates of analysis, stability data, and evidence of regulatory approvals from reputable authorities.

3How to Approach

Frequently Asked Questions — Al-kawkab Scientific Bureau

What products does Al-kawkab Scientific Bureau import from India?

Al-kawkab Scientific Bureau imports 3 pharmaceutical products across 3 categories. Top imports: Cefixime ($5.3M), Atorvastatin ($2.4M), Vildagliptin ($200.0K).

Who supplies pharmaceuticals to Al-kawkab Scientific Bureau from India?

Al-kawkab Scientific Bureau sources from 1 verified Indian suppliers. The primary supplier is Micro Labs Limited (100.0% of imports, $21.6M).

What is Al-kawkab Scientific Bureau's total pharmaceutical import value?

Al-kawkab Scientific Bureau's total pharmaceutical import value from India is $7.8M, based on 156 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Al-kawkab Scientific Bureau focus on?

Al-kawkab Scientific Bureau imports across 3 categories. The largest: Advanced Antibiotics (67.3%), Cardiovascular (30.1%), Advanced Diabetes Medications (2.6%).

Get Full Al-kawkab Scientific Bureau Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.